NCT02317627View on ClinicalTrials.gov

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Psoriasis Vulgaris
Interventions
DRUG

KD025

Trial Locations (9)

10029

Icahn School of Medicine at Mount Sinai, New York

16635

Altoona Center for Clinical Research, Duncansville

27265

High Point Clinical Trials Center, High Point

70605

Shondra L. Smith, Lake Charles

75231

Metroplex Clinical Research Center (MCRC), Dallas

85306

Arrowhead Health Centers, Glendale

89074

Clinical Studies Group, LLC, Henderson

92701

Southern California Dermatology, Inc., Santa Ana

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT02317627 - Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy | Biotech Hunter | Biotech Hunter